Risk, prevention and the breast cancer continuum: the NCI, the FDA, health activism and the pharmaceutical industry
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artikel |
| Sprache: | English |
| Veröffentlicht: |
2002
|
| Schlagworte: | |
| ISSN: | 0734-1512 |
Internformat
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV016476393 | ||
| 003 | DE-604 | ||
| 005 | 20111230 | ||
| 007 | t | ||
| 008 | 030130s2002 |||| 00||| eng d | ||
| 035 | |a (OCoLC)907792536 | ||
| 035 | |a (DE-599)BVBBV016476393 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-210 | ||
| 100 | 1 | |a Klawiter, Maren |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Risk, prevention and the breast cancer continuum |b the NCI, the FDA, health activism and the pharmaceutical industry |c Maren Klawiter |
| 264 | 1 | |c 2002 | |
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 648 | 7 | |a Geschichte 1998-2001 |2 gnd |9 rswk-swf | |
| 650 | 0 | 7 | |a Brustkrebs |0 (DE-588)4008528-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Tamoxifen |0 (DE-588)4184395-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |2 gnd |9 rswk-swf |
| 651 | 7 | |a USA |0 (DE-588)4078704-7 |2 gnd |9 rswk-swf | |
| 689 | 0 | 0 | |a USA |0 (DE-588)4078704-7 |D g |
| 689 | 0 | 1 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |D s |
| 689 | 0 | 2 | |a Brustkrebs |0 (DE-588)4008528-4 |D s |
| 689 | 0 | 3 | |a Tamoxifen |0 (DE-588)4184395-2 |D s |
| 689 | 0 | 4 | |a Geschichte 1998-2001 |A z |
| 689 | 0 | |5 DE-604 | |
| 773 | 1 | 8 | |g volume:18 |g number:4 |g year:2002 |g pages:309-353 |
| 773 | 0 | 8 | |t History and technology |d Abingdon |g 18 (2002),4, S. 309 - 353 |w (DE-604)BV002697814 |x 0734-1512 |o (DE-600)47030-2 |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-010186161 | ||
| 941 | |b 18 |h 4 |j 2002 |s 309-353 | ||
Datensatz im Suchindex
| _version_ | 1804129804049448960 |
|---|---|
| any_adam_object | |
| article_link | (DE-604)BV002697814 |
| author | Klawiter, Maren |
| author_facet | Klawiter, Maren |
| author_role | aut |
| author_sort | Klawiter, Maren |
| author_variant | m k mk |
| building | Verbundindex |
| bvnumber | BV016476393 |
| ctrlnum | (OCoLC)907792536 (DE-599)BVBBV016476393 |
| era | Geschichte 1998-2001 gnd |
| era_facet | Geschichte 1998-2001 |
| format | Article |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01469naa a2200397 c 4500</leader><controlfield tag="001">BV016476393</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20111230 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">030130s2002 |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)907792536</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV016476393</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-210</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Klawiter, Maren</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Risk, prevention and the breast cancer continuum</subfield><subfield code="b">the NCI, the FDA, health activism and the pharmaceutical industry</subfield><subfield code="c">Maren Klawiter</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2002</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="648" ind1=" " ind2="7"><subfield code="a">Geschichte 1998-2001</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Brustkrebs</subfield><subfield code="0">(DE-588)4008528-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Tamoxifen</subfield><subfield code="0">(DE-588)4184395-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Brustkrebs</subfield><subfield code="0">(DE-588)4008528-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Tamoxifen</subfield><subfield code="0">(DE-588)4184395-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="4"><subfield code="a">Geschichte 1998-2001</subfield><subfield code="A">z</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:18</subfield><subfield code="g">number:4</subfield><subfield code="g">year:2002</subfield><subfield code="g">pages:309-353</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="t">History and technology</subfield><subfield code="d">Abingdon</subfield><subfield code="g">18 (2002),4, S. 309 - 353</subfield><subfield code="w">(DE-604)BV002697814</subfield><subfield code="x">0734-1512</subfield><subfield code="o">(DE-600)47030-2</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-010186161</subfield></datafield><datafield tag="941" ind1=" " ind2=" "><subfield code="b">18</subfield><subfield code="h">4</subfield><subfield code="j">2002</subfield><subfield code="s">309-353</subfield></datafield></record></collection> |
| geographic | USA (DE-588)4078704-7 gnd |
| geographic_facet | USA |
| id | DE-604.BV016476393 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-09T19:10:57Z |
| institution | BVB |
| issn | 0734-1512 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-010186161 |
| oclc_num | 907792536 |
| open_access_boolean | |
| owner | DE-210 |
| owner_facet | DE-210 |
| publishDate | 2002 |
| publishDateSearch | 2002 |
| publishDateSort | 2002 |
| record_format | marc |
| spelling | Klawiter, Maren Verfasser aut Risk, prevention and the breast cancer continuum the NCI, the FDA, health activism and the pharmaceutical industry Maren Klawiter 2002 txt rdacontent n rdamedia nc rdacarrier Geschichte 1998-2001 gnd rswk-swf Brustkrebs (DE-588)4008528-4 gnd rswk-swf Tamoxifen (DE-588)4184395-2 gnd rswk-swf Pharmazeutische Industrie (DE-588)4045696-1 gnd rswk-swf USA (DE-588)4078704-7 gnd rswk-swf USA (DE-588)4078704-7 g Pharmazeutische Industrie (DE-588)4045696-1 s Brustkrebs (DE-588)4008528-4 s Tamoxifen (DE-588)4184395-2 s Geschichte 1998-2001 z DE-604 volume:18 number:4 year:2002 pages:309-353 History and technology Abingdon 18 (2002),4, S. 309 - 353 (DE-604)BV002697814 0734-1512 (DE-600)47030-2 |
| spellingShingle | Klawiter, Maren Risk, prevention and the breast cancer continuum the NCI, the FDA, health activism and the pharmaceutical industry Brustkrebs (DE-588)4008528-4 gnd Tamoxifen (DE-588)4184395-2 gnd Pharmazeutische Industrie (DE-588)4045696-1 gnd |
| subject_GND | (DE-588)4008528-4 (DE-588)4184395-2 (DE-588)4045696-1 (DE-588)4078704-7 |
| title | Risk, prevention and the breast cancer continuum the NCI, the FDA, health activism and the pharmaceutical industry |
| title_auth | Risk, prevention and the breast cancer continuum the NCI, the FDA, health activism and the pharmaceutical industry |
| title_exact_search | Risk, prevention and the breast cancer continuum the NCI, the FDA, health activism and the pharmaceutical industry |
| title_full | Risk, prevention and the breast cancer continuum the NCI, the FDA, health activism and the pharmaceutical industry Maren Klawiter |
| title_fullStr | Risk, prevention and the breast cancer continuum the NCI, the FDA, health activism and the pharmaceutical industry Maren Klawiter |
| title_full_unstemmed | Risk, prevention and the breast cancer continuum the NCI, the FDA, health activism and the pharmaceutical industry Maren Klawiter |
| title_short | Risk, prevention and the breast cancer continuum |
| title_sort | risk prevention and the breast cancer continuum the nci the fda health activism and the pharmaceutical industry |
| title_sub | the NCI, the FDA, health activism and the pharmaceutical industry |
| topic | Brustkrebs (DE-588)4008528-4 gnd Tamoxifen (DE-588)4184395-2 gnd Pharmazeutische Industrie (DE-588)4045696-1 gnd |
| topic_facet | Brustkrebs Tamoxifen Pharmazeutische Industrie USA |
| work_keys_str_mv | AT klawitermaren riskpreventionandthebreastcancercontinuumthencithefdahealthactivismandthepharmaceuticalindustry |